MK-2206 dihydrochloride

TargetMol
Product Code: TAR-T1952
Supplier: TargetMol
CodeSizePrice
TAR-T1952-2mg2mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-10mg10mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-25mg25mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-50mg50mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-100mg100mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1952-200mg200mg£371.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
MK-2206 is a highly specific inhibitor of Akt1/2/3 (IC50: 8/12/65 nM in cell-free assays) and no effect on the activities of 250 other protein kinases.
CAS:
1032350-13-2
Formula:
C25H23Cl2N5O
Molecular Weight:
480.39
Pathway:
Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Autophagy; Apoptosis
Purity:
0.9969
SMILES:
Cl.Cl.NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1
Target:
Apoptosis; Akt; Autophagy

References

1. Yan L. MK-2206: a potent oral allosteric AKT inhibitor. AACR Annual Meeting 2009: Abstract Number: DDT01-1. 10. Zhang L, Zhou Q, Qiu Q, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer[J]. Molecular Cancer. 2019, 18(1): 1-19. 2. Hirai H, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1956-67. 3. Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37. 4. Jin J, Zhao Y, Guo W, et al. Thiocoraline mediates drug resistance in MCF-7 cells via PI3K/Akt/BCRP signaling pathway[J]. Cytotechnology. 2019 Feb;71(1):401-409. 5. He J, Zhang A, Song Z, et al. The resistant effect of SIRT1 in oxidative stress-induced senescence of rat nucleus pulposus cell is regulated by Akt-FoxO1 pathway[J]. Bioscience reports. 2019 May 10;39(5). pii: BSR20190112. 6. Lv W, Huan M, Yang W, et al. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation[J]. Biochemical and Biophysical Research Communications. 2020, 529(3): 799-804. 7. Lv, Wei, et al. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation. Biochemical and Biophysical Research Communications . 529.3 (2020): 799-804. 8. Li Z, Zhou Z, Wu X, et al. LMP1 promotes nasopharyngeal carcinoma metastasis through NTRK2-mediated anoikis resistance[J]. American journal of cancer research . 2020, 10(7): 2083. 9. Zhou C, Du J, Zhao L, et al. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia[J]. Cell Death & Disease. 2021, 12(3): 1-14.